Harmony Biosciences (HRMY) 10-Q 3 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	Apr. 29, 2022
Cover [Abstract]
Entity Registrant Name	HARMONY BIOSCIENCES HOLDINGS, INC.
Entity Central Index Key	0001802665
Entity Tax Identification Number	82-2279923
Entity File Number	001-39450
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	630 W.
Entity Address, Address Line Two	Germantown Pike
Entity Address, Address Line Three	Suite 215
Entity Address, City or Town	Plymouth Meeting
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19462
City Area Code	484
Local Phone Number	539-9800
Title of 12(b) Security	Common Stock, par value $0.00001 value per share
Trading Symbol	HRMY
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		59,048,228

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 224,499	$ 234,309
Trade receivables, net	38,133	34,843
Inventory, net	4,597	4,432
Prepaid expenses	9,618	7,637
Other current assets	3,410	3,218
Total current assets	280,257	284,439
NONCURRENT ASSETS:
Property and equipment, net	748	820
Restricted cash	750	750
Intangible assets, net	178,837	143,919
Other noncurrent assets	3,413	3,515
Total noncurrent assets	183,748	149,004
TOTAL ASSETS	464,005	433,443
CURRENT LIABILITIES:
Trade payables	6,904	1,001
Accrued compensation	4,976	9,165
Accrued expenses	39,380	40,249
Current portion of long term debt	2,000	2,000
Other current liabilities	3,268	1,360
Total current liabilities	56,528	53,775
NONCURRENT LIABILITIES:
Long term debt, net	189,896	189,984
Other noncurrent liabilities	3,078	3,177
Total noncurrent liabilities	192,974	193,161
TOTAL LIABILITIES	249,502	246,936
COMMITMENTS AND CONTINGENCIES (Note10)
STOCKHOLDERS' EQUITY:
Common stock-$0.00001 par value; 500,000,000 shares authorized at March 31, 2022 and December 31, 2021, respectively; 59,030,148 shares and 58,825,769 issued and outstanding at March 31, 2022 and December 31, 2021, respectively	1	1
Additional paid in capital	646,615	640,104
Accumulated deficit	(432,113)	(453,598)
TOTAL STOCKHOLDERS' EQUITY	214,503	186,507
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 464,005	$ 433,443

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	59,030,148	58,825,769
Common stock, shares outstanding	59,030,148	58,825,769

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net product revenues	$ 85,313	$ 59,674
Cost of product sold	14,716	10,409
Gross profit	70,597	49,265
Operating expenses:
Research and development	7,578	4,679
Sales and marketing	17,583	15,506
General and administrative	17,880	14,547
Total operating expenses	43,041	34,732
Operating income	27,556	14,533
Other expense, net	(2)	(20)
Interest expense, net	(4,169)	(7,127)
Income before income taxes	23,385	7,386
Income tax expense	(1,900)
Net income and comprehensive income	$ 21,485	$ 7,386
EARNINGS PER SHARE:
Basic	$ 0.36	$ 0.13
Diluted	$ 0.35	$ 0.13
Weighted average number of shares of common stock - basic	58,908,526	56,891,451
Weighted average number of shares of common stock - diluted	60,586,875	58,805,285

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2020	$ 1	$ 585,374	$ (488,195)	$ 97,180
Beginning balance, shares at Dec. 31, 2020	56,890,569
Net income			7,386	7,386
Exercise of stock options		12		12
Exercise of stock options, Shares	1,837
Stock-based compensation		3,301		3,301
Ending balance at Mar. 31, 2021	$ 1	588,687	(480,809)	107,879
Ending balance, shares at Mar. 31, 2021	56,892,406
Beginning balance at Dec. 31, 2021	$ 1	640,104	(453,598)	186,507
Beginning balance, shares at Dec. 31, 2021	58,825,769
Net income			21,485	21,485
Exercise of stock options		1,883		$ 1,883
Exercise of stock options, Shares	204,379			205,432
Stock-based compensation		4,628		$ 4,628
Ending balance at Mar. 31, 2022	$ 1	$ 646,615	$ (432,113)	$ 214,503
Ending balance, shares at Mar. 31, 2022	59,030,148

UNAUDITED CONDENSED CONSOLIDA_5

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 21,485	$ 7,386
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation	117	100
Intangible amortization	5,082	4,579
Stock-based and employee stock purchase compensation expense	4,628	3,301
Stock appreciation rights market adjustment	268	(50)
Debt issuance costs amortization	412	664
Non-cash lease expense	385	264
Change in operating assets and liabilities:
Trade receivables	(3,290)	(1,439)
Inventory	(165)	(582)
Prepaid expenses and other assets	(2,235)	(296)
Trade payables	5,903	1,835
Accrued expenses and other current liabilities	(3,586)	(3,200)
Other non-current liabilities	(152)	(32)
Net cash provided by operating activities	28,852	12,530
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(45)	(4)
Milestone payments	(40,000)	(100,000)
Net cash used in investing activities	(40,045)	(100,004)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal repayment of long term debt	(500)
Proceeds from exercised options	1,883	12
Net cash provided by financing activities	1,383	12
NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(9,810)	(87,462)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-Beginning of period	235,059	229,381
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-End of period	225,249	141,919
Supplemental Disclosure of Cash Flow Information:
Cash paid during the year for interest	$ 3,829	$ 6,510

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARY NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (In thousands, except share and per share data) 1. ORGANIZATION AND DESCRIPTION OF BUSINESS The Company Harmony Biosciences Holdings, Inc. (the “Company”) was founded in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company, and the Company converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017. In February 2020, the Company changed its name to Harmony Biosciences Holdings, Inc. The Company is a holding company and has no operations. The Company’s operations are conducted in its wholly owned subsidiary, Harmony Biosciences, LLC (“Harmony”), which was formed in May 2017. The Company is a commercial-stage, rare disease pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological diseases who have unmet medical needs. The Company is headquartered in Plymouth Meeting, Pennsylvania. Initial Public Offering In August 2020, the Company completed its initial public offering (“IPO”) of common stock, in which it sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters’ over-allotment option. The shares were sold at an IPO price of $24.00 per share for net proceeds of approximately $135,435, after deducting underwriting discounts and commissions and offering expenses of approximately $12,193 payable by the Company. Upon the closing of the IPO, all outstanding shares of the Company’s convertible preferred stock were automatically converted into shares of common stock and the accrued dividend payable to holders of the convertible preferred stock was paid out in shares of common stock, resulting in a total of 42,926,630 shares of common stock being issued to former holders of the Company’s convertible preferred stock. Warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 410,239 shares of common stock.

Liquidity and Capital Resources

Liquidity and Capital Resources	3 Months Ended
	Mar. 31, 2022
Liquidity And Capital Resources [Abstract]
Liquidity and Capital Resources	2. The unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of $432,113 and $453,598, as of March 31, 2022 and December 31, 2021, respectively. As of March 31, 2022, the Company had cash and cash equivalents of $224,499. The Company believes that its existing cash and cash equivalents on hand as of March 31, 2022, as well as additional cash generated from operating and financing activities will meet its operational liquidity needs and fund its planned investing activities for the next twelve months from the date of issuance of these unaudited condensed consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of March 31, 2022, the unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three months ended March 31, 2022 and 2021, are unaudited. The balance sheet as of March 31, 2021 was derived from audited financial statements as of and for the year ended December 31, 2021. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2021, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2022, and the results of its operations and its cash flows for the three months ended March 31, 2022 and 2021. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and note disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The Company has updated certain prior period disclosures within Note 9 in order to conform with current period presentation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19. Fair Value of Financial Instruments The Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value. It is the Company’s policy, in general, to measure non-financial assets and liabilities at fair value on a nonrecurring basis. The instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes. The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities. Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows. ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 ​ 2021 Cash and cash equivalents ​ $ 224,499 ​ $ 234,309 Restricted cash ​ 750 ​ 750 Total cash, cash equivalents, and restricted cash shown in the statements of cash flows ​ $ 225,249 ​ $ 235,059 ​ Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program. Concentrations of Risk Substantially all of the Company’s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company is also subject to credit risk from its trade receivables related to its product sales. The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of March 31, 2022, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 38% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 32% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 30% of gross accounts receivable. As of December 31, 2021, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 40% of gross accounts receivable; Pantherx, which accounted for 31% of gross accounts receivable; and CVS Caremark, which accounted for 29% of gross accounts receivable. For the three months ended March 31, 2022, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 38% of gross product revenues; Pantherx accounted for 32% of gross product revenues; and Accredo accounted for 30% of gross product revenues. For the three months ended March 31, 2021 three customers accounted for 100% of gross product revenues; Pantherx accounted for 38% of gross product revenues CVS Caremark accounted for 35% of gross product revenues; and Accredo accounted for 27% of gross product revenues. The Company depends on a single source supplier for its product and active pharmaceutical ingredient. Agreement Related to Intellectual Property In August 2021, the Company entered into an asset purchase agreement with ConSynance Therapeutics, Inc. to acquire HBS-102 (formerly referred to as “CSTI-100”), a potential first-in-class molecule with a novel mechanism of action. Under the terms of the agreement, the Company acquired full development and commercialization rights globally, with the exception of Greater China, for $3,500. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset. Additionally, there are payments due upon the achievement of certain milestones including $1,750 for preclinical milestones, $19,000 for development milestones, $44,000 for regulatory milestones and $110,000 for sales milestones. Recently Issued Accounting Pronouncements ASU 2020-04, Reference Rate Reform (Topic 848). Reference Rate Reform (Topic 848)

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	4. INVENTORY Inventory, net consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 ​ 2021 Raw materials ​ $ 810 ​ $ 986 Work in process ​ 2,362 ​ 1,787 Finished goods ​ 1,874 ​ 2,108 Inventory, gross ​ 5,046 ​ 4,881 Reserve for excess inventory ​ (449) ​ (449) Total inventory, net ​ $ 4,597 ​ $ 4,432 ​

Intangible Asset

Intangible Asset	3 Months Ended
	Mar. 31, 2022
Intangible Assets Net Excluding Goodwill [Abstract]
Intangible Asset	5. INTANGIBLE ASSETS In August 2019, the Company received FDA approval of WAKIX (pitolisant) for the treatment of excessive daytime sleepiness (“EDS”) in adult patients with narcolepsy. This event triggered a milestone payment of $75,000 under the provisions of the License Agreement (defined below) which the Company capitalized as an intangible asset. The Company determined a useful life of 10 years for such intangible asset, and, as of March 31, 2022 the remaining useful life was 7.5 years. In October 2020, the Company received FDA approval for the New Drug Application (“NDA”) for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. This event triggered a milestone payment of $100,000 under the provisions of the License Agreement which the Company capitalized as an intangible asset and paid in January of 2021. The Company determined a useful life of 9 years for such intangible asset, and, as of March 31, 2022 the remaining useful life was 7.5 years. In February 2022, the Company attained $500,000 in aggregate net sales of WAKIX in the United States. This event triggered a final $40,000 payment under the provisions of the License Agreement which the Company capitalized as an intangible asset and paid in March of 2022. The Company determined a useful life of 7.6 years for such intangible asset, and, as of March 31, 2022 the remaining useful life was 7.5 years. Amortization expense was $5,082 and $4,579 for the three months ended March 31, 2022 and 2021, respectively, and is recorded in general and administrative expenses on the unaudited condensed consolidated statements of operations and comprehensive income (loss). The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows: ​ ​ ​ ​ ​ Years ending December 31, ​ ​ 2022 (Excluding the three months ended March 31, 2022) ​ $ 17,884 2023 ​ 23,845 2024 ​ 23,845 2025 ​ 23,845 2026 ​ 23,845 Thereafter ​ ​ 65,573 Total ​ $ 178,837 ​ The gross carrying amount and net book value of the intangible assets is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 ​ 2021 Gross Carrying Amount ​ $ 215,000 ​ $ 175,000 Accumulated Amortization ​ (36,163) ​ (31,081) Net Book Value ​ $ 178,837 ​ $ 143,919 ​

License Agreement

License Agreement	3 Months Ended
	Mar. 31, 2022
License Agreement [Abstract]
License Agreement	6. LICENSE AGREEMENT In July 2017, Harmony entered into the License Agreement (“the License Agreement”) with Bioprojet Société Civile de Recherche (“Bioprojet”) whereby Harmony acquired the exclusive right to commercialize the pharmaceutical compound pitolisant for the treatment, and/or prevention, of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and Parkinson’s disease as well as any other indications unanimously agreed by the parties in the United States and its territories. A milestone payment of $50,000 was due upon acceptance by the FDA of pitolisant’s NDA, which was achieved in February 2019 and was expensed within research and development for the year ended December 31, 2019. A milestone payment of $77,000, which included a $2,000 fee that is described below, was due upon FDA approval of WAKIX (pitolisant) for treatment of EDS in adult patients with narcolepsy, which was achieved in August 2019. The $2,000 payment and $75,000 milestone payment were paid in August and November 2019, respectively. In addition, a milestone payment of $102,000, which included a $2,000 fee was due upon the FDA approval of the NDA for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. The $2,000 payment was paid in October 2020 and a $100,000 milestone payment was paid in January 2021. A final $40,000 milestone payment was paid to Bioprojet in March 2022 upon WAKIX attaining $500,000 in aggregate net sales in the United States. The License Agreement also requires a fixed trademark royalty and a tiered royalty based on net sales, which is payable to Bioprojet on a quarterly basis. The Company incurred $13,672 and $9,547 for the three months ended March 31, 2022 and 2021, respectively, for sales-based, trademark and tiered royalties recognized as cost of product sold. As of March 31, 2022 and December 31, 2021, the Company had accrued $13,650 and $16,396, respectively, for sales-based, trademark and tiered royalties.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Payables And Accruals [Abstract]
Accrued Expenses	7. ACCRUED EXPENSES Accrued expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 ​ 2021 Royalties due to third parties ​ ​ 13,650 ​ ​ 16,396 Rebates and other sales deductions ​ 19,479 ​ 17,141 Interest ​ ​ 2,120 ​ ​ 2,125 Selling and marketing ​ 1,256 ​ 1,983 Research and development ​ 423 ​ 658 Professional fees, consulting, and other services ​ 1,554 ​ 1,645 Other expenses ​ 898 ​ 301 ​ ​ $ 39,380 ​ $ 40,249 ​

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	8. DEBT Credit Agreements Blackstone Credit Agreement In August 2021, the Company entered into the Blackstone Credit Agreement that provides for (i) a senior secured term loan facility in an aggregate original principal amount of $200,000 (the “Initial Term Loan”) and (ii) a senior secured delayed draw term loan facility in an aggregate principal amount up to $100,000 (the “DDTL” and, together with the Initial Term Loan, the “Loans”). The DDTL will be available to draw down through August 9, 2022. Long-term debt, net consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, December 31, ​ ​ 2022 ​ 2021 Liability component - principal ​ $ 199,000 ​ $ 199,500 Unamortized debt discount associated with debt financing costs ​ (7,104) ​ (7,516) Liability component - net carrying value ​ ​ 191,896 ​ ​ 191,984 Less current portion ​ ​ (2,000) ​ ​ (2,000) Long term debt, net ​ $ 189,896 ​ $ 189,984 ​ Future minimum payments relating to long term debt, net as of March 31, 2022 for the periods indicated below consists of the following: ​ ​ ​ ​ ​ Years ending December 31, ​ ​ ​ 2022 (Excluding the three months ended March 31, 2022) ​ $ 1,500 2023 ​ 2,000 2024 ​ 20,000 2025 ​ 20,000 2026 ​ 155,500 Thereafter ​ ​ — Total ​ $ 199,000 ​ Interest expense related to the Company’s long term debt, net, which is included in interest expense, net in the unaudited condensed consolidated statements of operations and comprehensive income (loss), consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ March 31, ​ ​ ​ 2022 2021 ​ Interest on principal balance ​ $ 3,824 ​ $ 6,510 ​ Amortization of deferred financing costs ​ 412 ​ 664 ​ Total term loan interest expense ​ $ 4,236 ​ $ 7,174 ​ ​

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 9. LEASES In June 2018, the Company entered into an operating lease for approximately fifteen thousand square feet of office space in Plymouth Meeting, PA, which expires in May 2024. In December 2020, the Company entered into an operating lease for approximately thirteen thousand square feet of additional office space in Plymouth Meeting, PA, which expires in May 2024. The terms of the lease payments provide for rental payments on a monthly basis and on a graduated scale. The Company also leases a fleet of automobiles that are used by its sales representatives and are classified as operating leases. The Company recorded operating lease costs of $385 and $264 for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, the weighted-average remaining lease term for operating leases was 2.3 years and the weighted-average discount rate for operating leases was 3.8%. Supplemental balance sheet information related to operating leases was as follows: ​ ​ ​ ​ ​ ​ ​ Leases Classification ​ March 31, 2022 ​ ​ December 31, 2021 Assets ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets Other noncurrent assets $ 3,134 ​ $ 3,298 Liabilities ​ ​ ​ ​ ​ ​ Operating lease liability, current portion Other current liabilities $ 1,535 ​ $ 1,527 Operating lease liability, long-term Other long-term liabilities ​ 2,018 ​ ​ 2,233 Total operating lease liabilities ​ $ 3,553 ​ $ 3,760 ​ Supplemental cash flow information related to operating leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ ​ March 31, 2021 Operating cash flows from operating leases $ 434 ​ $ 267 Right of use assets obtained in exchange for operating lease obligations (1) $ 234 ​ $ 1,958 (1) Including the balance recognized on January 1, 2021, upon adoption of ASU No. 2016-02. Future payments under noncancelable operating leases with initial terms of one year or more as of March 31, 2022 consisted of the following: ​ ​ ​ ​ Years ending December 31, ​ ​ 2022 (Excluding the three months ended March 31, 2022) ​ $ 1,240 2023 ​ 1,591 2024 ​ 866 2025 ​ 6 2026 ​ — Thereafter ​ — Total lease payments ​ ​ 3,703 Less: imputed interest ​ ​ (150) Total lease liabilities ​ $ 3,553 ​

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company is subject to claims and suits arising in the ordinary course of business. The Company accrues such liabilities when they are known, if they are deemed probable and can be reasonably estimated. As of March 31, 2022, there were no claims or suits outstanding. ​

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Stockholders Equity Note [Abstract]
Stockholders' Equity	11. STOCKHOLDERS’ EQUITY Common Stock The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the Company’s stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive ratably any dividends declared by the Company’s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Company’s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.

Stock Incentive Plan and Stock-

Stock Incentive Plan and Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Incentive Plan and Stock-based Compensation	12. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION 2020 Stock Incentive Plan In connection with the Company’s IPO, the board of directors adopted, and its stockholders approved, the 2020 Incentive Award Plan (the “2020 Plan”), in order to facilitate the grant of cash and equity incentives to directors, employees (including the Company’s named executive officers) and consultants of the Company and its subsidiaries. The 2020 Plan provides for the grant of stock options, including incentive stock options (“ISOs”) and non-qualified stock options (“NSOs”), SARs, restricted stock, dividend equivalents, restricted stock units (“RSUs”) and other stock or cash-based awards. Stock options and stock appreciation rights under the 2020 Plan have a 10-year contractual term and vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). RSUs vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). As of March 31, 2022, there were 5,089,156 shares of common stock reserved for issuance under the 2020 Plan. The number of shares that may be issued under the 2020 Plan will automatically increase on January 1 of each year in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors. 2017 Stock Incentive Plan On August 7, 2017, the Company adopted an equity incentive plan (the “2017 Plan”). Under the 2017 Plan, directors, officers, employees, consultants, and advisors of the Company can be paid incentive compensation measured by the value of the Company’s common shares through grants of stock options, stock appreciation rights (“SARs”), or restricted stock. Following the adoption of the 2020 Plan, no further grants have been, or will be, made under the 2017 Plan. However, the 2017 Plan will continue to govern the terms and conditions of outstanding awards granted under it. Stock Options The following table summarizes stock option activity for the three months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ Average ​ ​ ​ ​ Average ​ Remaining ​ ​ Number of ​ Exercise ​ Contractual ​ Awards Price Term Awards outstanding—December 31, 2021 5,716,597 ​ $ 22.53 8.09 Awards issued 1,377,307 ​ $ 49.33 Awards exercised (205,432) ​ $ 9.35 Awards forfeited (63,665) ​ $ 27.97 Awards outstanding—March 31, 2022 6,824,807 ​ $ 28.29 8.33 ​ Stock Appreciation Rights The following table summarizes SARs activity for the three months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ Average ​ ​ ​ ​ Average ​ Remaining ​ ​ Number of ​ Exercise ​ Contractual ​ Awards Price Term Awards outstanding—December 31, 2021 49,294 ​ $ 9.24 7.29 Awards issued — ​ $ — Awards exercised (3,651) ​ $ 8.22 Awards forfeited (2,435) ​ $ 8.22 Awards outstanding—March 31, 2022 43,208 ​ $ 9.38 7.08 ​ Restricted Stock Units The following table summarizes RSU activity for the three months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ Average ​ ​ ​ ​ Average ​ Remaining ​ ​ Number of ​ Exercise ​ Contractual ​ Awards Price Term Awards outstanding—December 31, 2021 60,000 ​ $ 29.03 9.24 Awards issued — ​ $ — Awards exercised — ​ $ — Awards forfeited — ​ $ — Awards outstanding—March 31, 2022 60,000 ​ $ 29.03 8.99 ​ As of March 31, 2022 and December 31, 2021, stock awards issued under the 2017 and 2020 Plans of 1,225,948 and 1,285,432 common shares, respectively, were vested. Value of Stock Options and SARs The Company has valued awards for each of the plans included herein using the Black-Scholes option-pricing model. The Company lacks sufficient historical company-specific volatility information. Therefore, the Company estimates expected stock volatility based on historical volatility of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. For SARs, the expected term is based upon the weighting of certain future events. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for the time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The assumptions used to value the awards are summarized in the following table. ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 2021 ​ Dividend yield 0.00 % 0.00 % Expected volatility 72.60-72.70 % 60.00 % Risk-free interest rate 1.99 - 2.37 % 0.66 - 1.44 % Expected term (years) 3.9 - 6.3 4.1- 6.3 ​ ​ Value of RSUs The fair value of RSUs is equal to the value of the Company’s common stock on the grant date. The weighted average per share fair value of awards issued under the 2017 Plan and 2020 Plan was $16.94 and $12.82 on March 31, 2022 and December 31, 2021, respectively. Stock-Based Compensation Stock-based compensation expense, net for the three months ended March 31, 2022 and 2021, was recorded in the unaudited condensed consolidated statements of operations and comprehensive income in the following line items: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2022 2021 Research and development expense ​ $ 518 ​ $ 420 Sales and marketing expense ​ 976 ​ 620 General and administrative expense ​ 3,402 ​ 2,211 ​ ​ $ 4,896 ​ $ 3,251 ​ Options and RSUs issued under the 2017 Plan and 2020 Plan are included in stockholder’s equity, and SARs are included in other non-current liabilities, in the Company’s unaudited condensed consolidated balance sheet. As of March 31, 2022, the total unrecognized stock-based compensation expense related to Options and RSUs was $95,566. Such amount will be recognized in the Company’s consolidated statement of operations over a weighted average period of 3.5 years. ​ Employee Stock Purchase Plan The 2021 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors on April 30, 2021. The ESPP permits eligible employees to purchase shares of the Company’s common stock at a 15% discount from the lesser of the fair market value per share of the Company’s common stock on the first day of the offering period or the fair market value of the Company’s common stock on the purchase date. Funds are collected from employees through after-tax payroll deductions. The total number of shares reserved for issuance under the ESPP was initially 629,805, which will automatically increase on January 1 of each year in an amount equal to the lesser of (i) 1.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors. It is intended that the ESPP meet the requirements for an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. For the three months ended March 31, 2022, there were no shares issued under the ESPP. The discount on the ESPP for the three months ended March 31, 2022 was $94 and is recorded within stock-based compensation expense.

Earnings per Share

Earnings per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Earnings per Share	13. EARNINGS PER SHARE The Company has reported net income for both the three months ended March 31, 2022 and 2021. Diluted net income per common share is computed under the treasury stock method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options, stock appreciation rights, restricted stock units and warrants. In addition, the Company analyzes the potential dilutive effects of the outstanding convertible preferred stock under the ‘if-converted’ method when calculating diluted earnings per share, in which it is assumed that the outstanding convertible preferred stock converts into common stock at the beginning of the period or when issued if later. The Company reports the more dilutive of the approaches (treasury stock or ‘if converted’) as its diluted net income per share during the period. The following table sets forth the computation of basic and diluted net income per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2022 2021 Numerator ​ ​ Net income ​ $ 21,485 ​ $ 7,386 Denominator ​ ​ Net income per common share - basic ​ $ 0.36 ​ $ 0.13 Net income per common share - diluted ​ $ 0.35 ​ $ 0.13 Weighted average number of shares of common stock - basic ​ 58,908,526 ​ 56,891,451 Weighted average number of shares of common stock - diluted ​ 60,586,875 ​ 58,805,285 ​ Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2022 2021 Stock options, SARs, and RSUs to purchase common stock ​ ​ 1,678,349 ​ ​ 1,691,882 Warrants ​ ​ — ​ ​ 221,953 Total ​ ​ 1,678,349 ​ ​ 1,913,835 ​ Potential common shares issuable upon exercise of stock options, and exercise of warrants that were excluded from the computation of diluted weighted-average shares outstanding as well as the warrant fair value adjustments excluded from the numerator are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ ​ 2022 2021 Stock options, SARs, and RSUs to purchase common stock ​ 5,249,666 ​ 4,683,323 ​ Warrants ​ — ​ 188,286 ​ Total ​ 5,249,666 ​ 4,871,609 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Related-party Transactions

Related-party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related-party Transactions	14. RELATED-PARTY TRANSACTIONS The Company was party to a management agreement for professional services provided by a related party, Paragon Biosciences, LLC (“Paragon”). The related party is an entity that shares common ownership with the Company. In addition, the Chairman of the Company’s board of directors was the President and owner of the entity. The Company terminated the management agreement upon the consummation of its IPO. The Company is also party to a right of use agreement with the related party whereby it has access to and the right to use certain office space leased by the related party in Chicago, Illinois. In addition, the Company had participated in certain transactions with separate related parties that also share common ownership with the Company, primarily related to combined employee health plans. The Company incurred $ 71 for each of the three months ended March 31, 2022 and 2021, in expenses to this related party, which are included in general and administrative expense in the unaudited condensed consolidated statements of operations and comprehensive loss. As of March 31, 2022 and December 31, 2021, there were no amounts due to or due from related parties included in the unaudited condensed consolidated balance sheets.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of March 31, 2022, the unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three months ended March 31, 2022 and 2021, are unaudited. The balance sheet as of March 31, 2021 was derived from audited financial statements as of and for the year ended December 31, 2021. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2021, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2022, and the results of its operations and its cash flows for the three months ended March 31, 2022 and 2021. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and note disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The Company has updated certain prior period disclosures within Note 9 in order to conform with current period presentation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value. It is the Company’s policy, in general, to measure non-financial assets and liabilities at fair value on a nonrecurring basis. The instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes. The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities. Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows. ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 ​ 2021 Cash and cash equivalents ​ $ 224,499 ​ $ 234,309 Restricted cash ​ 750 ​ 750 Total cash, cash equivalents, and restricted cash shown in the statements of cash flows ​ $ 225,249 ​ $ 235,059 ​ Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.
Concentrations of Risk	Concentrations of Risk Substantially all of the Company’s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company is also subject to credit risk from its trade receivables related to its product sales. The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of March 31, 2022, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 38% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 32% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 30% of gross accounts receivable. As of December 31, 2021, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 40% of gross accounts receivable; Pantherx, which accounted for 31% of gross accounts receivable; and CVS Caremark, which accounted for 29% of gross accounts receivable. For the three months ended March 31, 2022, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 38% of gross product revenues; Pantherx accounted for 32% of gross product revenues; and Accredo accounted for 30% of gross product revenues. For the three months ended March 31, 2021 three customers accounted for 100% of gross product revenues; Pantherx accounted for 38% of gross product revenues CVS Caremark accounted for 35% of gross product revenues; and Accredo accounted for 27% of gross product revenues. The Company depends on a single source supplier for its product and active pharmaceutical ingredient.
Agreement Related to Intellectual Property	Agreement Related to Intellectual Property In August 2021, the Company entered into an asset purchase agreement with ConSynance Therapeutics, Inc. to acquire HBS-102 (formerly referred to as “CSTI-100”), a potential first-in-class molecule with a novel mechanism of action. Under the terms of the agreement, the Company acquired full development and commercialization rights globally, with the exception of Greater China, for $3,500. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset. Additionally, there are payments due upon the achievement of certain milestones including $1,750 for preclinical milestones, $19,000 for development milestones, $44,000 for regulatory milestones and $110,000 for sales milestones.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements ASU 2020-04, Reference Rate Reform (Topic 848). Reference Rate Reform (Topic 848)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows. ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 ​ 2021 Cash and cash equivalents ​ $ 224,499 ​ $ 234,309 Restricted cash ​ 750 ​ 750 Total cash, cash equivalents, and restricted cash shown in the statements of cash flows ​ $ 225,249 ​ $ 235,059

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory Net	Inventory, net consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 ​ 2021 Raw materials ​ $ 810 ​ $ 986 Work in process ​ 2,362 ​ 1,787 Finished goods ​ 1,874 ​ 2,108 Inventory, gross ​ 5,046 ​ 4,881 Reserve for excess inventory ​ (449) ​ (449) Total inventory, net ​ $ 4,597 ​ $ 4,432

Intangible Asset (Tables)

Intangible Asset (Tables)	3 Months Ended
	Mar. 31, 2022
Intangible Assets Net Excluding Goodwill [Abstract]
Schedule of Expected Future Annual Amortization Expense for Unamortized Intangible Assets	The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows: ​ ​ ​ ​ ​ Years ending December 31, ​ ​ 2022 (Excluding the three months ended March 31, 2022) ​ $ 17,884 2023 ​ 23,845 2024 ​ 23,845 2025 ​ 23,845 2026 ​ 23,845 Thereafter ​ ​ 65,573 Total ​ $ 178,837
Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets	The gross carrying amount and net book value of the intangible assets is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 ​ 2021 Gross Carrying Amount ​ $ 215,000 ​ $ 175,000 Accumulated Amortization ​ (36,163) ​ (31,081) Net Book Value ​ $ 178,837 ​ $ 143,919

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 ​ 2021 Royalties due to third parties ​ ​ 13,650 ​ ​ 16,396 Rebates and other sales deductions ​ 19,479 ​ 17,141 Interest ​ ​ 2,120 ​ ​ 2,125 Selling and marketing ​ 1,256 ​ 1,983 Research and development ​ 423 ​ 658 Professional fees, consulting, and other services ​ 1,554 ​ 1,645 Other expenses ​ 898 ​ 301 ​ ​ $ 39,380 ​ $ 40,249

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Balances of Long-term debt, net	Long-term debt, net consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, December 31, ​ ​ 2022 ​ 2021 Liability component - principal ​ $ 199,000 ​ $ 199,500 Unamortized debt discount associated with debt financing costs ​ (7,104) ​ (7,516) Liability component - net carrying value ​ ​ 191,896 ​ ​ 191,984 Less current portion ​ ​ (2,000) ​ ​ (2,000) Long term debt, net ​ $ 189,896 ​ $ 189,984
Future Minimum Payments Relating to Long Term Debt	Future minimum payments relating to long term debt, net as of March 31, 2022 for the periods indicated below consists of the following: ​ ​ ​ ​ ​ Years ending December 31, ​ ​ ​ 2022 (Excluding the three months ended March 31, 2022) ​ $ 1,500 2023 ​ 2,000 2024 ​ 20,000 2025 ​ 20,000 2026 ​ 155,500 Thereafter ​ ​ — Total ​ $ 199,000
Interest Expense Related to Long Term Debt	Interest expense related to the Company’s long term debt, net, which is included in interest expense, net in the unaudited condensed consolidated statements of operations and comprehensive income (loss), consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ March 31, ​ ​ ​ 2022 2021 ​ Interest on principal balance ​ $ 3,824 ​ $ 6,510 ​ Amortization of deferred financing costs ​ 412 ​ 664 ​ Total term loan interest expense ​ $ 4,236 ​ $ 7,174 ​

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of supplemental balance sheet and cash flow information related to operating leases	Supplemental balance sheet information related to operating leases was as follows: ​ ​ ​ ​ ​ ​ ​ Leases Classification ​ March 31, 2022 ​ ​ December 31, 2021 Assets ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets Other noncurrent assets $ 3,134 ​ $ 3,298 Liabilities ​ ​ ​ ​ ​ ​ Operating lease liability, current portion Other current liabilities $ 1,535 ​ $ 1,527 Operating lease liability, long-term Other long-term liabilities ​ 2,018 ​ ​ 2,233 Total operating lease liabilities ​ $ 3,553 ​ $ 3,760 ​ Supplemental cash flow information related to operating leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ ​ March 31, 2021 Operating cash flows from operating leases $ 434 ​ $ 267 Right of use assets obtained in exchange for operating lease obligations (1) $ 234 ​ $ 1,958 (1) Including the balance recognized on January 1, 2021, upon adoption of ASU No. 2016-02.
Schedule of future payments under noncancelable operating leases	Future payments under noncancelable operating leases with initial terms of one year or more as of March 31, 2022 consisted of the following: ​ ​ ​ ​ Years ending December 31, ​ ​ 2022 (Excluding the three months ended March 31, 2022) ​ $ 1,240 2023 ​ 1,591 2024 ​ 866 2025 ​ 6 2026 ​ — Thereafter ​ — Total lease payments ​ ​ 3,703 Less: imputed interest ​ ​ (150) Total lease liabilities ​ $ 3,553

Stock Incentive Plan and Stoc_2

Stock Incentive Plan and Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Changes in Stock Options Granted	The following table summarizes stock option activity for the three months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ Average ​ ​ ​ ​ Average ​ Remaining ​ ​ Number of ​ Exercise ​ Contractual ​ Awards Price Term Awards outstanding—December 31, 2021 5,716,597 ​ $ 22.53 8.09 Awards issued 1,377,307 ​ $ 49.33 Awards exercised (205,432) ​ $ 9.35 Awards forfeited (63,665) ​ $ 27.97 Awards outstanding—March 31, 2022 6,824,807 ​ $ 28.29 8.33
Summary of Changes in SARs Granted	The following table summarizes SARs activity for the three months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ Average ​ ​ ​ ​ Average ​ Remaining ​ ​ Number of ​ Exercise ​ Contractual ​ Awards Price Term Awards outstanding—December 31, 2021 49,294 ​ $ 9.24 7.29 Awards issued — ​ $ — Awards exercised (3,651) ​ $ 8.22 Awards forfeited (2,435) ​ $ 8.22 Awards outstanding—March 31, 2022 43,208 ​ $ 9.38 7.08
Summary of Changes in RSUs Granted	The following table summarizes RSU activity for the three months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ Average ​ ​ ​ ​ Average ​ Remaining ​ ​ Number of ​ Exercise ​ Contractual ​ Awards Price Term Awards outstanding—December 31, 2021 60,000 ​ $ 29.03 9.24 Awards issued — ​ $ — Awards exercised — ​ $ — Awards forfeited — ​ $ — Awards outstanding—March 31, 2022 60,000 ​ $ 29.03 8.99
Summary of Assumptions Used to Value Awards	The assumptions used to value the awards are summarized in the following table. ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ March 31, December 31, ​ ​ 2022 2021 ​ Dividend yield 0.00 % 0.00 % Expected volatility 72.60-72.70 % 60.00 % Risk-free interest rate 1.99 - 2.37 % 0.66 - 1.44 % Expected term (years) 3.9 - 6.3 4.1- 6.3 ​
Summary of Stock-based Compensation Expense	Stock-Based Compensation Stock-based compensation expense, net for the three months ended March 31, 2022 and 2021, was recorded in the unaudited condensed consolidated statements of operations and comprehensive income in the following line items: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2022 2021 Research and development expense ​ $ 518 ​ $ 420 Sales and marketing expense ​ 976 ​ 620 General and administrative expense ​ 3,402 ​ 2,211 ​ ​ $ 4,896 ​ $ 3,251

Earnings per Share (Tables)

Earnings per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Income per Share	The following table sets forth the computation of basic and diluted net income per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2022 2021 Numerator ​ ​ Net income ​ $ 21,485 ​ $ 7,386 Denominator ​ ​ Net income per common share - basic ​ $ 0.36 ​ $ 0.13 Net income per common share - diluted ​ $ 0.35 ​ $ 0.13 Weighted average number of shares of common stock - basic ​ 58,908,526 ​ 56,891,451 Weighted average number of shares of common stock - diluted ​ 60,586,875 ​ 58,805,285
Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share	Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2022 2021 Stock options, SARs, and RSUs to purchase common stock ​ ​ 1,678,349 ​ ​ 1,691,882 Warrants ​ ​ — ​ ​ 221,953 Total ​ ​ 1,678,349 ​ ​ 1,913,835 ​ Potential common shares issuable upon exercise of stock options, and exercise of warrants that were excluded from the computation of diluted weighted-average shares outstanding as well as the warrant fair value adjustments excluded from the numerator are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ ​ 2022 2021 Stock options, SARs, and RSUs to purchase common stock ​ 5,249,666 ​ 4,683,323 ​ Warrants ​ — ​ 188,286 ​ Total ​ 5,249,666 ​ 4,871,609 ​ ​ ​ ​ ​ ​ ​ ​ ​

Organization and Description _2

Organization and Description of Business - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended
	Aug. 31, 2020USD ($)$ / sharesshares
Organization And Description Of Business [Line Items]
Purchase of common stock upon exercise of warrants	410,239
Common Stock
Organization And Description Of Business [Line Items]
Common stock issued	42,926,630
Common Stock | IPO
Organization And Description Of Business [Line Items]
Issuance of common stock (in shares)	6,151,162
Shares issued, price per share | $ / shares	$ 24
Proceeds from issuance of common stock upon initial public offering | $	$ 135,435
Underwriting discounts and commissions and offering expenses | $	$ 12,193
Common Stock | Over-Allotment Option
Organization And Description Of Business [Line Items]
Issuance of common stock (in shares)	802,325

Liquidity and Capital Resourc_2

Liquidity and Capital Resources - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Liquidity And Capital Resources [Abstract]
Accumulated deficit	$ 432,113	$ 453,598
Cash and cash equivalents	$ 224,499	$ 234,309

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 224,499	$ 234,309
Restricted cash	750	750
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$ 225,249	$ 235,059	$ 141,919	$ 229,381

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 31, 2021USD ($)	Mar. 31, 2022USD ($)customer	Mar. 31, 2021customer	Dec. 31, 2021USD ($)customer
Summary Of Significant Accounting Policies [Line Items]
Operating lease right-of-use assets		$ 3,134		$ 3,298
Short-term operating lease liabilities		1,535		1,527
Long-term operating lease liabilities		$ 2,018		$ 2,233
Asset Purchase Agreement with ConSynance Therapeutics [Member] | HBS-102 | All Countries Excluding Greater China
Summary Of Significant Accounting Policies [Line Items]
Consideration transferred	$ 3,500
Payment for intellectual property upon preclinical milestones	1,750
Payment for intellectual property upon developmental milestones	19,000
Payment for intellectual property upon regulatory milestones	44,000
Payment for intellectual property upon sales milestones	$ 110,000
Three Customers | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Number of customers | customer		3		3
Concentration risk percentage		100.00%		100.00%
Three Customers | Product Revenues | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Number of customers | customer		3	3
Concentration risk percentage		100.00%	100.00%
Caremark LLC | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		38.00%		29.00%
Caremark LLC | Product Revenues | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		38.00%	35.00%
PANTHERx Specialty Pharmacy LLC | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		30.00%		31.00%
PANTHERx Specialty Pharmacy LLC | Product Revenues | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		32.00%	38.00%
Accredo Health Group, Inc | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		32.00%		40.00%
Accredo Health Group, Inc | Product Revenues | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		30.00%	27.00%

Inventory - Schedule of Invento

Inventory - Schedule of Inventory Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 810	$ 986
Work in process	2,362	1,787
Finished goods	1,874	2,108
Inventory, gross	5,046	4,881
Reserve for excess inventory	(449)	(449)
Total inventory, net	$ 4,597	$ 4,432

Intangible Asset - Additional I

Intangible Asset - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended				3 Months Ended
	Feb. 28, 2022	Jan. 31, 2021	Nov. 30, 2019	Aug. 31, 2019	Mar. 31, 2022	Mar. 31, 2021
Finite Lived Intangible Assets [Line Items]
License agreement milestone payments paid			$ 75,000	$ 2,000
Amortization expense					$ 5,082	$ 4,579
Net product revenues					85,313	$ 59,674
WAKIX
Finite Lived Intangible Assets [Line Items]
Final payment paid					$ 40,000
Useful life of intangible asset					7 years 7 months 6 days
Remaining useful life					7 years 6 months
WAKIX | United States
Finite Lived Intangible Assets [Line Items]
Net product revenues	$ 500,000
WAKIX | Daytime Sleepiness
Finite Lived Intangible Assets [Line Items]
License agreement milestone payments paid			$ 75,000
Useful life of intangible asset					10 years
Remaining useful life					7 years 6 months
NDA for WAKIX. | Cataplexy
Finite Lived Intangible Assets [Line Items]
License agreement milestone payments paid		$ 100,000
Useful life of intangible asset		9 years
Remaining useful life					7 years 6 months

Intangible Asset - Schedule of

Intangible Asset - Schedule of Expected Future Annual Amortization Expense for Unamortized Intangible Assets (Details) $ in Thousands	Mar. 31, 2022USD ($)
Finite Lived Intangible Assets Net Amortization Expense Fiscal Maturity [Abstract]
2022 (Excluding the three months ended March 31, 2022)	$ 17,884
2023	23,845
2024	23,845
2025	23,845
2026	23,845
Thereafter	65,573
Total	$ 178,837

Intangible Asset - Schedule o_2

Intangible Asset - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Intangible Assets Net Excluding Goodwill [Abstract]
Gross Carrying Amount	$ 215,000	$ 175,000
Accumulated Amortization	(36,163)	(31,081)
Net Book Value	$ 178,837	$ 143,919

License Agreement - Additional

License Agreement - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended				3 Months Ended
	Jan. 31, 2021	Oct. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Feb. 12, 2019
License Agreement [Line Items]
Licensing agreement milestone fees				$ 2,000
License agreement milestone payments paid			$ 75,000	2,000
License agreement, additional milestone payment due				102,000
Cost of product sold					$ 14,716	$ 10,409
Accrued Sales Based Trademark and Royalties					13,650		$ 16,396
Upon Acceptance by FDA of Pitolisant's
License Agreement [Line Items]
License agreement, milestone payment due								$ 50,000
Upon FDA Approval of WAKIX
License Agreement [Line Items]
License agreement, milestone payment due				77,000
Licensing agreement milestone fees				$ 2,000
License agreement milestone payments paid	$ 100,000	$ 2,000
Sales-based, Trademark and Tiered Royalties
License Agreement [Line Items]
Cost of product sold					13,672	$ 9,547
Bioprojet | United States
License Agreement [Line Items]
Amount of Aggregate Net Sales Attaining					500,000
Bioprojet | Attaining $500,000 Aggregate Net Sales | United States | Upon FDA Approval of WAKIX
License Agreement [Line Items]
Final payment paid					$ 40,000

Accrued Expenses -Schedule of A

Accrued Expenses -Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Royalties due to third parties	$ 13,650	$ 16,396
Rebates and other sales deductions	19,479	17,141
Interest	2,120	2,125
Selling and marketing	1,256	1,983
Research and development	423	658
Professional fees, consulting, and other services	1,554	1,645
Other expenses	898	301
Accrued expenses	$ 39,380	$ 40,249

Debt - Additional Information (

Debt - Additional Information (Details) - Blackstone Alternative Credit Advisors ("Blackstone") - USD ($) $ in Thousands	1 Months Ended
	Aug. 31, 2021	Mar. 31, 2022
Senior Secured Term Loan
Debt Instrument [Line Items]
Aggregate principal amount	$ 200,000
Debt issuance costs	8,151
Cash proceeds received	$ 191,849
Term of loan	5 years
Fair value of loan		$ 169,966
Senior Secured Term Loan | Repayment of Debt Commencing on December 31, 2021
Debt Instrument [Line Items]
Periodic payment principal	$ 500
Senior Secured Term Loan | Repayment of Debt Beginning on March 31, 2024
Debt Instrument [Line Items]
Periodic payment principal	5,000
Senior Secured Term Loan | Repayment of Debt Due on Maturity Date
Debt Instrument [Line Items]
Periodic payment principal	$ 145,500
Senior Secured Term Loan | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	6.50%
Senior Secured Term Loan | London Interbank Offered Rate (LIBOR) [Member] | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Senior Secured Delayed Draw Term Loan
Debt Instrument [Line Items]
Aggregate principal amount	$ 100,000
Debt issuance costs	$ 1,000

Debt - Balances of Long-term De

Debt - Balances of Long-term Debt, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Liability component - principal	$ 199,000	$ 199,500
Unamortized debt discount associated with debt financing costs	(7,104)	(7,516)
Liability component - net carrying value	191,896	191,984
Less current portion	(2,000)	(2,000)
Long term debt, net	$ 189,896	$ 189,984

Debt - Future Minimum Payments

Debt - Future Minimum Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Long-term Debt, Fiscal Year Maturity [Abstract]
2022 (Excluding the three months ended March 31, 2022)	$ 1,500
2023	2,000
2024	20,000
2025	20,000
2026	155,500
Total	$ 199,000	$ 199,500

Debt - Interest Expense (Detail

Debt - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Disclosure [Abstract]
Interest on principal balance	$ 3,824	$ 6,510
Amortization of deferred financing costs	412	664
Total term loan interest expense	$ 4,236	$ 7,174

Leases (Details)

Leases (Details) ft² in Thousands, $ in Thousands	1 Months Ended		3 Months Ended
	Dec. 31, 2018ft²	Jun. 30, 2018ft²	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Lessee, Lease, Description [Line Items]
Operating lease square feet of office space | ft²	13	15
Lessee, Operating Lease, Existence of Option to Extend [true false]			true
Lessee, Operating Lease, Existence of Option to Terminate [true false]			true
Cost operating lease | $			$ 385	$ 264
Weighted average remaining lease term			2 years 3 months 18 days
Weighted-average discount rate for operating leases			3.80%
Minimum
Lessee, Lease, Description [Line Items]
Lease terms			1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease terms			3 years

Leases - Supplemental balance s

Leases - Supplemental balance sheet information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Operating lease right-of-use assets	$ 3,134	$ 3,298
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets Noncurrent	Other Assets Noncurrent
Liabilities
Operating lease liability, current portion	$ 1,535	$ 1,527
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other Liabilities Current	Other Liabilities Current
Operating lease liability, long-term	$ 2,018	$ 2,233
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities Noncurrent	Other Liabilities Noncurrent
Total operating lease liabilities	$ 3,553	$ 3,760

Leases - Supplemental cash flow

Leases - Supplemental cash flow information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating cash flows from operating leases	$ 434	$ 267
Right of use assets obtained in exchange for operating lease obligations (1)	$ 234	$ 1,958

Leases - Future payments (Detai

Leases - Future payments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Years ending December 31,
2022 (Excluding the three months ended March 31, 2022)	$ 1,240
2023	1,591
2024	866
2025	6
Total lease payments	3,703
Less: imputed interest	(150)
Total operating lease liabilities	$ 3,553	$ 3,760

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Mar. 31, 2022claim
Commitments And Contingencies Disclosure [Abstract]
Claims or suits outstanding	0

Stockholders' Equity (Details)

Stockholders' Equity (Details)	3 Months Ended
	Mar. 31, 2022
Stockholders Equity Note [Abstract]
Common stock, voting rights	one vote for each share

Stock Incentive Plan and Stoc_3

Stock Incentive Plan and Stock-based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense		$ 95,566
Weighted average period		3 years 6 months
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average per share fair value of awards issued (in USD per share)		$ 16.94	$ 12.82
2020 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options contractual term		10 years
Percentage of increment of common stock outstanding		4.00%
Total number of shares reserved for issuance		5,089,156
2017 and 2020 Plans | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock vested		1,225,948	1,285,432
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of increment of common stock outstanding	1.00%
ESPP permits eligible employees to purchase shares of common stock at discount	15.00%
Total number of shares reserved for issuance	629,805
Shares issued under the ESPP		0
Amount of discount on ESSP		$ 94

Stock Incentive Plan and Stoc_4

Stock Incentive Plan and Stock-based Compensation - Summary of Changes in Stock Options Granted (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Awards, Awards outstanding, Beginning balance	5,716,597
Number of Awards, Awards issued	1,377,307
Number of Awards, Awards exercised	(205,432)
Number of Awards, Awards forfeited	(63,665)
Number of Awards, Awards outstanding, Ending balance	6,824,807	5,716,597
Weighted-Average Exercise Price, Awards outstanding, Beginning balance	$ 22.53
Weighted-Average Exercise Price, Awards issued	49.33
Weighted-Average Exercise Price, Awards exercised	9.35
Weighted-Average Exercise Price, Awards forfeited	27.97
Weighted-Average Exercise Price, Awards outstanding, Ending balance	$ 28.29	$ 22.53
Weighted-Average Remaining Contractual Term	8 years 3 months 29 days	8 years 1 month 2 days

Stock Incentive Plan and Stoc_5

Stock Incentive Plan and Stock-based Compensation - Summary of Changes in SARs Granted (Details) - Stock Appreciation Rights - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Awards, Awards outstanding, Beginning balance	49,294
Number of Awards, Awards exercised	(3,651)
Number of Awards, Awards forfeited	(2,435)
Number of Awards, Awards outstanding, Ending balance	43,208	49,294
Weighted-Average Exercise Price, Awards outstanding, Beginning balance	$ 9.24
Weighted-Average Exercise Price, Awards exercised	8.22
Weighted-Average Exercise Price, Awards forfeited	8.22
Weighted-Average Exercise Price, Awards outstanding, Ending balance	$ 9.38	$ 9.24
Weighted-Average Remaining Contractual Term	7 years 29 days	7 years 3 months 14 days

Stock Incentive Plan and Stoc_6

Stock Incentive Plan and Stock-based Compensation - Summary of Changes in RSUs Granted (Details) - Restricted Stock Units - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Awards, Awards outstanding, Beginning balance	60,000
Number of Awards, Awards outstanding, Ending balance	60,000	60,000
Weighted-Average Exercise Price, Awards outstanding, Beginning balance	$ 29.03
Weighted-Average Exercise Price, Awards outstanding, Ending balance	$ 29.03	$ 29.03
Weighted-Average Remaining Contractual Term	8 years 11 months 26 days	9 years 2 months 26 days

Stock Incentive Plan and Stoc_7

Stock Incentive Plan and Stock-based Compensation - Summary of Assumptions Used to Value Awards (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility		60.00%
Expected volatility, minimum	72.60%
Expected volatility, maximum	72.70%
Risk-free interest rate, minimum	1.99%	0.66%
Risk-free interest rate, maximum	2.37%	1.44%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	3 years 10 months 24 days	4 years 1 month 6 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	6 years 3 months 18 days	6 years 3 months 18 days

Stock Incentive Plan and Stoc_8

Stock Incentive Plan and Stock-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,896	$ 3,251
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	518	420
Sales and Marketing Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	976	620
General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 3,402	$ 2,211

Earnings per Share - Summary of

Earnings per Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator
Net income	$ 21,485	$ 7,386
Denominator
Net income per common share - basic	$ 0.36	$ 0.13
Net income per common share - diluted	$ 0.35	$ 0.13
Weighted average number of shares of common stock - basic	58,908,526	56,891,451
Weighted average number of shares of common stock - diluted	60,586,875	58,805,285

Earnings per Share - Summary _2

Earnings per Share - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	1,678,349	1,913,835
Stock options, SARs, and RSUs to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	1,678,349	1,691,882
Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total		221,953

Earnings per Share - Summary _3

Earnings per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	5,249,666	4,871,609
Stock options, SARs, and RSUs to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	5,249,666	4,683,323
Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total		188,286

Related-party Transactions - Ad

Related-party Transactions - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Amounts due to or due from related parties	$ 0		$ 0
Management Services Agreement | General and Administrative Expense
Related Party Transaction [Line Items]
Management fee expense and other expenses to related party	$ 71	$ 71